Israel, Remote Patient Monitoring, Tel Aviv, Wearable Telehealth Technology
Utilization of wearable telehealth technology for remote patient monitoring is validated by new Sheba medical center study
July 2022: Peer-reviewed study analyzes usability of a wearable RPM device, which detected early warning of risk for ABCNO deterioration in 75% of patients, 38 hours on average before actual clinical deterioration RAMAT GA..
HIFU, Istanbul, Turkey
Focal HIFU therapy in prostate cancer
What does local prostate cancer mean? In Liv Hospital Urology Clinic, HIFU is applied as the primary treatment approach in localized prostate cancer, that is, at the stage where the entire cancer is in the prostate tissue and ..
CAR - T Cell therapy, Seoul, South Korea
AMC opens up CAR T-Cell therapy center in Seoul
Jan 2023: The Asan Medical Center (AMC) opened the first CAR-T cell treatment facility in the country after the government approved health insurance benefits for Kymriah's CAR-T cell therapy.AMC announced on Tuesday that its canc..
Genentech, Lunsumio, mosunetuzumab-axgb, refractory follicular lymphoma
Mosunetuzumab-axgb is granted accelerated approval for relapsed or refractory follicular lymphoma
Jan 2023: Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) following two or more rounds of systemic therapy, rece..
Adstiladrin, Bacillus Calmette-Guérin, Ferring Pharmaceuticals, nadofaragene firadenovec-vncg
First adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer is approved by FDA
Jan 2023: The drug nadofaragene firadenovec-vncg (Adstiladrin, Ferring Pharmaceuticals) has been approved by the Food and Drug Administration for adult patients with high-risk, unresponsive non-muscle invasive bladder cancer (NMIB..
adagrasib, Krazati, Mirati Therapeutics, NSCLC, QIAGEN, RAS GTPase family inhibitor
Adagrasib gets accelerated approval for KRAS G12C-mutated NSCLC
Jan 2023: Adagrasib (Krazati, Mirati Therapeutics, Inc.), a RAS GTPase family inhibitor, was given accelerated approval by the Food and Drug Administration (FDA) for adult patients with KRAS G12C-mutated locally advanced or metast..
Brexucabtagene autoleucel, European Union, Gilead, Kite, Tecartus
Tecartus granted European marketing authorization for treatment of relapsed or refractory acute lymphoblastic leukemia
Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or refractory (r/r) B-cell precurs..
Bristol Myers Squibb, CHECKMATE-648, esophageal squamous cell carcinoma, NCT03143153, nivolumab, Opdivo, Yervoy
Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy is approved by FDA for first-line esophageal squamous cell carcinoma indications
June 2022: For the first-line therapy of individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), the Food and Drug Administration has approved the following:In combination with fluoropyrimidine- and pla..
World Cancer Day 2022
4th Feb 2022: In India, cancer can have serious social and economic effects, typically resulting in family destitution and societal injustice. In this demographically young country, reported age-adjusted cancer incidence rates are..
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Drugs approved for treatment of liver cancer
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..